Jiunn-Chang Lin

614 total citations
27 papers, 426 citations indexed

About

Jiunn-Chang Lin is a scholar working on Oncology, Cancer Research and Surgery. According to data from OpenAlex, Jiunn-Chang Lin has authored 27 papers receiving a total of 426 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 7 papers in Cancer Research and 6 papers in Surgery. Recurrent topics in Jiunn-Chang Lin's work include Hepatocellular Carcinoma Treatment and Prognosis (4 papers), Cancer, Hypoxia, and Metabolism (3 papers) and Cancer Immunotherapy and Biomarkers (3 papers). Jiunn-Chang Lin is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (4 papers), Cancer, Hypoxia, and Metabolism (3 papers) and Cancer Immunotherapy and Biomarkers (3 papers). Jiunn-Chang Lin collaborates with scholars based in Taiwan, United States and France. Jiunn-Chang Lin's co-authors include Tsang‐Pai Liu, Pei‐Ming Yang, Chien‐Liang Liu, Chun‐Chi Lin, Hung-Kai Chen, Ying‐Ju Kuo, Shyh‐Kuan Tai, Muh‐Hwa Yang, Jie-Jen Lee and Chih‐Hsiung Wu and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Jiunn-Chang Lin

27 papers receiving 421 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jiunn-Chang Lin Taiwan 11 152 150 124 84 79 27 426
Guo‐Liang Shen China 12 149 1.0× 206 1.4× 135 1.1× 93 1.1× 89 1.1× 48 464
Biao Zheng China 10 184 1.2× 126 0.8× 67 0.5× 68 0.8× 77 1.0× 28 373
Yanping Zhong China 14 172 1.1× 161 1.1× 72 0.6× 74 0.9× 83 1.1× 37 476
Yifei Mu China 14 140 0.9× 228 1.5× 94 0.8× 46 0.5× 133 1.7× 27 457
Haoyue Hu China 11 163 1.1× 251 1.7× 101 0.8× 96 1.1× 140 1.8× 31 524
Eunsun Jung South Korea 13 110 0.7× 228 1.5× 79 0.6× 45 0.5× 102 1.3× 40 504
Zehua Wang China 13 185 1.2× 275 1.8× 126 1.0× 103 1.2× 187 2.4× 32 562
Judit López‐Luque Spain 8 95 0.6× 179 1.2× 80 0.6× 56 0.7× 70 0.9× 8 368
Nicole Liscia Italy 7 226 1.5× 131 0.9× 73 0.6× 112 1.3× 104 1.3× 29 374

Countries citing papers authored by Jiunn-Chang Lin

Since Specialization
Citations

This map shows the geographic impact of Jiunn-Chang Lin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jiunn-Chang Lin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jiunn-Chang Lin more than expected).

Fields of papers citing papers by Jiunn-Chang Lin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jiunn-Chang Lin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jiunn-Chang Lin. The network helps show where Jiunn-Chang Lin may publish in the future.

Co-authorship network of co-authors of Jiunn-Chang Lin

This figure shows the co-authorship network connecting the top 25 collaborators of Jiunn-Chang Lin. A scholar is included among the top collaborators of Jiunn-Chang Lin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jiunn-Chang Lin. Jiunn-Chang Lin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Lin, Jiunn-Chang, Tsang‐Pai Liu, Yanbin Chen, & Pei‐Ming Yang. (2023). PF-429242 exhibits anticancer activity in hepatocellular carcinoma cells via FOXO1-dependent autophagic cell death and IGFBP1-dependent anti-survival signaling.. PubMed. 13(9). 4125–4144. 6 indexed citations
3.
Lin, Jiunn-Chang, et al.. (2023). Inhibition of CDK9 exhibits anticancer activity in hepatocellular carcinoma cells via targeting ribonucleotide reductase. Toxicology and Applied Pharmacology. 471. 116568–116568. 2 indexed citations
4.
Su, Yung‐Yeh, Chin‐Fu Hsiao, Da‐Liang Ou, et al.. (2021). P-124 Nivolumab plus ipilimumab as neoadjuvant therapy for potentially resectable hepatocellular carcinoma. Annals of Oncology. 32. S141–S141. 10 indexed citations
5.
Lin, Jiunn-Chang, Chien‐Liang Liu, Yuan‐Ching Chang, et al.. (2021). Trilostane, a 3β-hydroxysteroid dehydrogenase inhibitor, suppresses growth of hepatocellular carcinoma and enhances anti-cancer effects of sorafenib. Investigational New Drugs. 39(6). 1493–1506. 6 indexed citations
6.
Liu, Chien‐Liang, Ming‐Jen Chen, Jiunn-Chang Lin, et al.. (2019). Doxorubicin Promotes Migration and Invasion of Breast Cancer Cells through the Upregulation of the RhoA/MLC Pathway. Journal of Breast Cancer. 22(2). 185–185. 36 indexed citations
7.
Chang, Yuan‐Ching, Chi‐Hsin Lin, Jiunn-Chang Lin, et al.. (2019). Inhibition of 3β-Hydroxysteroid Dehydrogenase Type 1 Suppresses Interleukin-6 in Breast Cancer. Journal of Surgical Research. 241. 8–14. 4 indexed citations
8.
Lin, Jiunn-Chang, Ying‐Ju Kuo, Hung-Kai Chen, et al.. (2018). Macrophage-secreted interleukin-35 regulates cancer cell plasticity to facilitate metastatic colonization. Nature Communications. 9(1). 3763–3763. 116 indexed citations
9.
Ko, Wen‐Chin, et al.. (2017). Surgical management of primary retroperitoneal tumors – Analysis of a single center experience. Journal of Cancer Research and Practice. 4(2). 49–52. 4 indexed citations
10.
Chang, Yuan‐Ching, Chi‐Kuan Chen, Ming‐Jen Chen, et al.. (2017). Expression of 3β-Hydroxysteroid Dehydrogenase Type 1 in Breast Cancer is Associated with Poor Prognosis Independent of Estrogen Receptor Status. Annals of Surgical Oncology. 24(13). 4033–4041. 16 indexed citations
11.
Liu, Chia‐Yuan, Ching‐Chung Lin, Jiunn-Chang Lin, et al.. (2015). Pleural Effusion after Percutaneous Radiofrequency Ablation for Hepatic Malignancies. SHILAP Revista de lepidopterología. 4 indexed citations
12.
Liu, Chien‐Liang, et al.. (2014). Goblet Cell Carcinoid of Appendix. Journal of Cancer Research and Practice. 1(1). 82–87. 4 indexed citations
13.
Lin, Jiunn-Chang, Wei‐Pang Huang, Chien‐Liang Liu, et al.. (2013). Sorafenib Induces Autophagy in Human Myeloid Dendritic Cells and Prolongs Survival of Skin Allografts. Transplantation. 95(6). 791–800. 17 indexed citations
14.
Lin, Jiunn-Chang, Shih‐Ping Cheng, Wen‐Chin Ko, et al.. (2013). Synchronous Primary Adenocarcinoma and Gastrointestinal Stromal Tumor of the Stomach in an Elderly Patient. International journal of gerontology. 7(4). 241–242. 1 indexed citations
15.
Lin, Jiunn-Chang, Chien‐Liang Liu, Jie-Jen Lee, et al.. (2013). Sorafenib induces autophagy and suppresses activation of human macrophage. International Immunopharmacology. 15(2). 333–339. 40 indexed citations
16.
Antonarakis, Emmanuel S., Jiunn-Chang Lin, Daniel Keizman, Michael A. Carducci, & Mario A. Eisenberger. (2010). The effect of changes in PSA kinetics on metastasis-free survival (MFS) in patients with PSA-recurrent prostate cancer (PC) treated with nonhormonal agents: Combined analysis of three randomized trials.. Journal of Clinical Oncology. 28(15_suppl). 4549–4549. 2 indexed citations
17.
Lin, Jiunn-Chang, et al.. (2009). Increased percentage of B cells in patients with more advanced hepatocellular carcinoma. Human Immunology. 71(1). 58–62. 10 indexed citations
18.
Lin, Jiunn-Chang, et al.. (2008). Carcinoid Tumors of the Appendix-Experience in a Teaching Hospital. 24(1). 17–20. 1 indexed citations
19.
Lin, Jiunn-Chang, et al.. (2006). Induction of apoptosis and cell-cycle arrest in human colon cancer cells by meclizine. Food and Chemical Toxicology. 45(6). 935–944. 27 indexed citations
20.
Lin, Jiunn-Chang, Chien‐Liang Liu, Tsang‐Pai Liu, Kuo‐Shyang Jeng, & Tsen‐Long Yang. (2002). The Sonographic Findings of Mondor's Disease in the Breast. Journal of Medical Ultrasound. 10(4). 202–204. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Guo‐Liang Shen Breakdown of academic impact, for papers by Biao Zheng Breakdown of academic impact, for papers by Yanping Zhong Breakdown of academic impact, for papers by Yifei Mu Breakdown of academic impact, for papers by Haoyue Hu Breakdown of academic impact, for papers by Eunsun Jung Breakdown of academic impact, for papers by Zehua Wang Breakdown of academic impact, for papers by Judit López‐Luque Breakdown of academic impact, for papers by Nicole Liscia
Rankless by CCL
2026